Abstract

Gait is impaired in musculoskeletal conditions, such as knee arthropathy. Gait analysis is used in clinical practice to inform diagnosis and to monitor disease progression or intervention response. However, clinical gait analysis relies on subjective visual observation of walking, as objective gait analysis has not been possible within clinical settings due to the expensive equipment, large-scale facilities, and highly trained staff required. Relatively low-cost wearable digital insoles may offer a solution to these challenges. In this work, we demonstrate how a digital insole measuring osteoarthritis-specific gait signatures yields similar results to the clinical gait-lab standard. To achieve this, we constructed a machine learning model, trained on force plate data collected in participants with knee arthropathy and controls. This model was highly predictive of force plate data from a validation set (area under the receiver operating characteristics curve [auROC] = 0.86; area under the precision-recall curve [auPR] = 0.90) and of a separate, independent digital insole dataset containing control and knee osteoarthritis subjects (auROC = 0.83; auPR = 0.86). After showing that digital insole derived gait characteristics are comparable to traditional gait measurements, we next showed that a single stride of raw sensor time series data could be accurately assigned to each subject, highlighting that individuals using digital insoles can be identified by their gait characteristics. This work provides a framework for a promising alternative to traditional clinical gait analysis methods, adds to the growing body of knowledge regarding wearable technology analytical pipelines, and supports clinical development of at-home gait assessments, with the potential to improve the ease, frequency, and depth of patient monitoring.

Data availability

Anonymized data and computer code to reproduce all figures will be made available as supplementary files to this manuscript. All relevant demographic and clinical information, all vGRF, derived gait characteristics, and raw sensor time series data, will be provided, in addition to R and Python scripts used to perform the analysis. Additionally, this information will be uploaded to a Regeneron GitHub account here: https://github.com/regeneron-mpds. This data will be made fully available prior to final publication of this manuscript. The GaitRec dataset is available online here: https://www.nature.com/articles/s41597-020-0481-z

Article and author information

Author details

  1. Matthew F Wipperman

    Precision Medicine, Regeneron, Tarrytown, United States
    For correspondence
    matthew.wipperman@regeneron.com
    Competing interests
    Matthew F Wipperman, Employee and shareholder of Regeneron Pharmaceuticals, Inc..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1436-3366
  2. Allen Z Lin

    Molecular Profiling and Data Science, Regeneron, Tarrytown, United States
    Competing interests
    Allen Z Lin, Employee and shareholder of Regeneron Pharmaceuticals, Inc..
  3. Kaitlyn M Gayvert

    Molecular Profiling and Data Science, Regeneron, Tarrytown, United States
    Competing interests
    Kaitlyn M Gayvert, Employee and shareholder of Regeneron Pharmaceuticals, Inc..
  4. Benjamin Lahner

    Precision Medicine, Regeneron, Tarrytown, United States
    Competing interests
    Benjamin Lahner, Employee and shareholder of Regeneron Pharmaceuticals, Inc..
  5. Selin Somersan-Karakaya

    Early Clinical Development and Experimental Sciences, Regeneron, Tarrytown, United States
    Competing interests
    Selin Somersan-Karakaya, Employee and shareholder of Regeneron Pharmaceuticals, Inc..
  6. Xuefang Wu

    Clinical Outcomes Assessment and Patient Innovation, Regeneron, Tarrytown, United States
    Competing interests
    Xuefang Wu, Employee and shareholder of Regeneron Pharmaceuticals, Inc..
  7. Joseph Im

    Clinical Outcomes Assessment and Patient Innovation, Regeneron, Tarrytown, United States
    Competing interests
    Joseph Im, Employee and shareholder of Regeneron Pharmaceuticals, Inc..
  8. Minji Lee

    Molecular Profiling and Data Science, Regeneron, Tarrytown, United States
    Competing interests
    Minji Lee, Employee and shareholder of Regeneron Pharmaceuticals, Inc..
  9. Bharatkumar Koyani

    Clinical Outcomes Assessment and Patient Innovation, Regeneron, Tarrytown, United States
    Competing interests
    Bharatkumar Koyani, Employee and shareholder of Regeneron Pharmaceuticals, Inc..
  10. Ian Setliff

    Molecular Profiling and Data Science, Regeneron, Tarrytown, United States
    Competing interests
    Ian Setliff, Employee and shareholder of Regeneron Pharmaceuticals, Inc..
  11. Malika Thakur

    Clinical Outcomes Assessment and Patient Innovation, Regeneron, Tarrytown, United States
    Competing interests
    Malika Thakur, Employee and shareholder of Regeneron Pharmaceuticals, Inc..
  12. Daoyu Duan

    Precision Medicine, Regeneron, Tarrytown, United States
    Competing interests
    Daoyu Duan, Employee and shareholder of Regeneron Pharmaceuticals, Inc..
  13. Aurora Breazna

    Biostatistics and Data Management, Regeneron, Tarrytown, United States
    Competing interests
    Aurora Breazna, Employee and shareholder of Regeneron Pharmaceuticals, Inc..
  14. Fang Wang

    Precision Medicine, Regeneron, Tarrytown, United States
    Competing interests
    Fang Wang, Employee and shareholder of Regeneron Pharmaceuticals, Inc..
  15. Wei Keat Lim

    Molecular Profiling and Data Science, Regeneron, Tarrytown, United States
    Competing interests
    Wei Keat Lim, Employee and shareholder of Regeneron Pharmaceuticals, Inc..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6226-2570
  16. Gabor Halasz

    Molecular Profiling and Data Science, Regeneron, Tarrytown, United States
    Competing interests
    Gabor Halasz, Employee and shareholder of Regeneron Pharmaceuticals, Inc..
  17. Jacek Urbanek

    Biostatistics and Data Management, Regeneron, Tarrytown, United States
    Competing interests
    Jacek Urbanek, Employee and shareholder of Regeneron Pharmaceuticals, Inc..
  18. Yamini Patel

    General Medicine, Regeneron, Tarrytown, United States
    Competing interests
    Yamini Patel, Employee and shareholder of Regeneron Pharmaceuticals, Inc..
  19. Gurinder S Atwal

    Molecular Profiling and Data Science, Regeneron, Tarrytown, United States
    Competing interests
    Gurinder S Atwal, Employee and shareholder of Regeneron Pharmaceuticals, Inc..
  20. Jennifer D Hamilton

    Precision Medicine, Regeneron, Tarrytown, United States
    Competing interests
    Jennifer D Hamilton, Employee and shareholder of Regeneron Pharmaceuticals, Inc..
  21. Samuel Stuart

    Precision Medicine, Regeneron, Tarrytown, United States
    Competing interests
    Samuel Stuart, Employee and stockholder of Regeneron Pharmaceuticals, Inc..
  22. Oren Levy

    Early Clinical Development and Experimental Sciences, Regeneron, Tarrytown, United States
    Competing interests
    Oren Levy, Employee and shareholder of Regeneron Pharmaceuticals, Inc..
  23. Andreja Avbersek

    Early Clinical Development and Experimental Sciences, Regeneron, Tarrytown, United States
    Competing interests
    Andreja Avbersek, Employee and shareholder of Regeneron Pharmaceuticals, Inc..
  24. Rinol Alaj

    Clinical Outcomes Assessment and Patient Innovation, Regeneron, Tarrytown, United States
    For correspondence
    rinol.alaj@regeneron.com
    Competing interests
    Rinol Alaj, Employee and shareholder of Regeneron Pharmaceuticals, Inc..
  25. Sara C Hamon

    Precision Medicine, Regeneron, Tarrytown, United States
    For correspondence
    sara.hamon@regeneron.com
    Competing interests
    Sara C Hamon, Employee and shareholder of Regeneron Pharmaceuticals, Inc..
  26. Olivier Harari

    Early Clinical Development and Experimental Sciences, Regeneron, Tarrytown, United States
    For correspondence
    olivier.harari@regeneron.com
    Competing interests
    Olivier Harari, Employee and shareholder of Regeneron Pharmaceuticals, Inc..

Funding

Regeneron Pharmaceuticals (N/A)

  • Matthew F Wipperman
  • Allen Z Lin
  • Kaitlyn M Gayvert
  • Benjamin Lahner
  • Selin Somersan-Karakaya
  • Xuefang Wu
  • Joseph Im
  • Minji Lee
  • Bharatkumar Koyani
  • Ian Setliff
  • Malika Thakur
  • Daoyu Duan
  • Aurora Breazna
  • Fang Wang
  • Wei Keat Lim
  • Gabor Halasz
  • Jacek Urbanek
  • Yamini Patel
  • Gurinder S Atwal
  • Jennifer D Hamilton
  • Oren Levy
  • Andreja Avbersek
  • Rinol Alaj
  • Sara C Hamon
  • Olivier Harari

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Human subjects: For the pilot study, participants were recruited internally within the Regeneron facility located in Tarrytown, NY, USA, and were provided written informed consent prior to participation. The study was considered exempt research under the Common Rule (45 CFR Sec 46.104). The R5069-OA-1849 study protocol received Institutional Review Board and ethics committee approvals from Moldova Medicines and Medical Device Agency and National Ethics Committee for Moldova, and the Western Institutional Review Board.

Copyright

© 2024, Wipperman et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 986
    views
  • 143
    downloads
  • 0
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Matthew F Wipperman
  2. Allen Z Lin
  3. Kaitlyn M Gayvert
  4. Benjamin Lahner
  5. Selin Somersan-Karakaya
  6. Xuefang Wu
  7. Joseph Im
  8. Minji Lee
  9. Bharatkumar Koyani
  10. Ian Setliff
  11. Malika Thakur
  12. Daoyu Duan
  13. Aurora Breazna
  14. Fang Wang
  15. Wei Keat Lim
  16. Gabor Halasz
  17. Jacek Urbanek
  18. Yamini Patel
  19. Gurinder S Atwal
  20. Jennifer D Hamilton
  21. Samuel Stuart
  22. Oren Levy
  23. Andreja Avbersek
  24. Rinol Alaj
  25. Sara C Hamon
  26. Olivier Harari
(2024)
Digital wearable insole-based identification of knee arthropathies and gait signatures using machine learning
eLife 13:e86132.
https://doi.org/10.7554/eLife.86132

Share this article

https://doi.org/10.7554/eLife.86132

Further reading

    1. Medicine
    2. Microbiology and Infectious Disease
    Kavidha Reddy, Guinevere Q Lee ... Thumbi Ndung'u
    Research Article

    Persisting HIV reservoir viruses in resting CD4 T cells and other cellular subsets are a barrier to cure efforts. Early antiretroviral therapy (ART) enables post-treatment viral control in some cases, but mechanisms remain unclear. We hypothesised that ART initiated before peak viremia impacts HIV-1 subtype C reservoirs. We studied 35 women at high risk of infection from Durban, South Africa, identified with hyperacute HIV by twice-weekly HIV-RNA testing. Participants included 11 starting ART at a median of 456 (297–1203) days post-onset of viremia (DPOV) and 24 at 1 (1–3) DPOV. Peripheral blood mononuclear cells (PBMCs) were used to measured total HIV-1 DNA by droplet digital PCR (ddPCR) and sequence viral reservoir genomes by full-length proviral sequencing (FLIP-seq). ART during hyperacute infection blunted peak viremia (p<0.0001), but contemporaneous total HIV-1 DNA did not differ (p=0.104). Over 1 year, a decline of total HIV-1 DNA was observed in early treated persons (p=0.0004), but not late treated. Among 697 viral genome sequences, the proviral genetic landscape differed between untreated, late treated, and early treated groups. Intact genomes after 1 year were higher in untreated (31%) versus late treated (14%) and early treated (0%). Treatment in both late and early infection caused more rapid decay of intact (13% and 51% per month) versus defective (2% and 35%) viral genomes. However, intact genomes persisted 1 year post chronic treatment but were undetectable with early ART. Early ART also reduced phylogenetic diversity of intact genomes and limited cytotoxic T lymphocyte immune escape variants in the reservoir. Overall, ART initiated in hyperacute HIV-1 subtype C infection did not impact reservoir seeding but was associated with rapid intact viral genome decay, reduced genetic complexity, and limited immune escape, which may accelerate reservoir clearance in combination with other interventional strategies.

    1. Cancer Biology
    2. Medicine
    Patrick Brandt, Dawayne Whittington ... Rebekah L Layton
    Research Article

    A doctoral-level internship program was developed at the University of North Carolina at Chapel Hill with the intent to create customizable experiential learning opportunities for biomedical trainees to support career exploration, preparation, and transition into their postgraduate professional roles. We report the outcomes of this program over a 5-year period. During that 5-year period, 123 internships took place at over 70 partner sites, representing at least 20 academic, for-profit, and non-profit career paths in the life sciences. A major goal of the program was to enhance trainees’ skill development and expertise in careers of interest. The benefits of the internship program for interns, host/employer, and supervisor/principal investigator were assessed using a mixed-methods approach, including surveys with closed- and open-ended responses as well as focus group interviews. Balancing stakeholder interests is key to creating a sustainable program with widespread support; hence, the level of support from internship hosts and faculty members were the key metrics analyzed throughout. We hypothesized that once a successful internship program was implemented, faculty culture might shift to be more accepting of internships; indeed, the data quantifying faculty attitudes support this. Furthermore, host motivation and performance expectations of interns were compared with results achieved, and this data revealed both expected and surprising benefits to hosts. Data suggests a myriad of benefits for each stakeholder group, and themes are cataloged and discussed. Program outcomes, evaluation data, policies, resources, and best practices developed through the implementation of this program are shared to provide resources that facilitate the creation of similar internship programs at other institutions. Program development was initially spurred by National Institutes of Health pilot funding, thereafter, successfully transitioning from a grant-supported model, to an institutionally supported funding model to achieve long-term programmatic sustainability.